Medpace Retail Trader Optimism Abounds As Stock Poised For Best Day Ever On Q2 Beat, Outlook

Shares of Medpace Holdings, Inc. (MEDP) trended on Stocktwits following the company's quarterly results and outlook, which exceeded expectations.

The company is a full-service contract research organization (CRO), providing Phase I through IV clinical development services to the biotechnology, pharmaceutical, and medical device industries.

Medpace stock rose by over 45% in overnight trading as traders welcomed the financial results for the second quarter of fiscal year 2025.

On Stocktwits, retail sentiment toward the stock inflected higher to 'extremely bullish' (97/100) by late Monday, from 'neutral' a day ago. The message volume also picked up pace to 'extremely high' levels.

A bullish watcher said the strong after-hours reaction went on to prove how oversold healthcare stocks were.“Is this a preview of $UNH and future health stocks that are oversold...,” they wondered.

Another user flaunted their bet on Medpace stock that paid off. They said,“$MEDP bought 10K calls just for the bell 90K net profit 900% for the moment, regret I did not buy more.”

Cincinnati, Ohio-based Medpace reported second-quarter GAAP net income of $90.3 million or $3.10 per share compared to $88.4 million or $2.75 per share a year ago. Revenue climbed 14.2% year over year (YoY) to $603.3 million. 

Both metrics exceeded the Koyfin-compiled consensus of $2.97 and $539 million, respectively.

Net new business awards jumped 12.6% YoY to $620.5 million, translating to a book-to-bill ratio of 1.03 times. 

The adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) were $130.47 million, compared to $112.25 million, with an adjusted EBITDA margin of 21.6% versus 21.3% a year ago.

Medpace guided 2025 revenue to be in the range of $2.42 billion to $2.52 billion, marking a 14.7% to 19.5% increase, and earnings per share in the range of $13.76 to $14.53.

Analysts, on average, estimate revenue of $2.19 billion and GAAP earnings per share of $12.74, respectively.

Medpace stock is down over 7% so far this year. If the overnight gains are sustained on Tuesday, the stock is on track to record its biggest ever single-day gain.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

MENAFN22072025007385015968ID1109829835